SEC Form 4 · accession 0001209191-16-111161
aTYR PHARMA INC · LIFE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kelly Blackburn
Officer — VP, Clinical Affairs
Period of report
Mar 28, 2016
Accepted (ET)
Mar 30, 2016 · 9:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001339970
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitF1,F2 | — | Mar 28, 2016 | A | 21,600 | A | — | — | Common Stock | 21,600 | 21,600 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F21/2 of the restricted stock units are scheduled to vest on March 28, 2017 and the remaining 1/2 are scheduled to vest on March 28, 2018. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.